🔎 Trials Near Me

Home › Head and Neck Squamous Cell Carcinoma › Nebraska

Head and Neck Squamous Cell Carcinoma clinical trials in Nebraska

15 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in Nebraska.

Cities in Nebraska

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

  • Nebraska Cancer Specialists, Omaha
  • XCancer, Omaha
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07189871

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  • NHO Revive Research Institute, LLC, Lincoln
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07276399

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

  • Nebraska Medicine-Bellevue, Bellevue
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05136196

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Nebraska Cancer Specialists, Omaha
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07109726

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  • CHI Health Saint Francis, Grand Island
  • CHI Health Good Samaritan, Kearney
  • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
  • and 4 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06769698

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

  • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
  • Nebraska Methodist Hospital, Omaha
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04333537

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #2, Omaha
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT05176483

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Nebraska Cancer Specialists, Omaha
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT04198766

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  • GSK Investigational Site, Omaha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT06256588

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  • USA14-0, Lincoln
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT06953089

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

  • Nebraska Medicine-Bellevue, Bellevue
  • Nebraska Methodist Hospital, Omaha
  • Nebraska Medicine-Village Pointe, Omaha
  • and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 11, 2026 · NCT06992427

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

  • Nebraska Cancer Specialists, Omaha
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Feb 18, 2026 · NCT07030257

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.